© accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy
The SME F4 Pharma is a bio-pharmaceutical company established 2020 in Vienna. The company aims to convert high impact scientific discovery into pharmaceutical products for orphan diseases with high medical need. They develop and commercialise pharmaceuticals targeting capillary leak syndrome and systemic inflammation.
Consortium partner F4 Pharma is developing an innovative drug called FX06 in diseases associated with systemic inflammation and capillary leak. With its new mode of action – not comparable to any drug on the market – FX06 is targeting a fundamental mechanism within the endothelial cells of the blood vessels thus restoring and maintaining physiological permeability. A ph II study with FX06 in ARDS patients is in the center of the COVend project and data from these patients – in combination with in vitro investigations – serve as basis for elucidation of the molecular mechanism behind ARDS.
Innovation Manager of the COVend consortium
F4-PharmaChief Scientific Officer
Work package leader of WP2: FX06 preparation for clinical trial (CMC Chemistry, manufacturing & control)
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]
© accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy